Oguic R, Grskovic A, Spanjol J, Mikolasevic I, Djordjevic G
Medicina (Kaunas). 2025; 60(12.
PMID: 39768912
PMC: 11728140.
DOI: 10.3390/medicina60122032.
Quan Y, Wang M, Zhang H, Lu D, Ping H
iScience. 2024; 27(12):111351.
PMID: 39650727
PMC: 11625293.
DOI: 10.1016/j.isci.2024.111351.
Cirillo N
Curr Oncol. 2024; 31(9):5140-5150.
PMID: 39330008
PMC: 11431433.
DOI: 10.3390/curroncol31090380.
Quan Y, Zhang H, Wang M, Ping H
Comput Struct Biotechnol J. 2024; 23:3315-3326.
PMID: 39310280
PMC: 11414276.
DOI: 10.1016/j.csbj.2024.08.026.
Cimadamore A, Cheng L, Lopez-Beltran A, Franzese C, Giannarini G, Crestani A
Virchows Arch. 2024; .
PMID: 39153109
DOI: 10.1007/s00428-024-03891-9.
Impact of the diagnostic label for a low-risk prostate lesion: protocol for two online factorial randomised experiments.
Bullen J, Nickel B, McCaffery K, Wilt T, Smith J, Boroumand F
BMJ Open. 2024; 14(8):e085947.
PMID: 39122400
PMC: 11331948.
DOI: 10.1136/bmjopen-2024-085947.
Risk of Cancer-related Death for Men with Biopsy Grade Group 1 Prostate Cancer and High-risk Features: A European Multi-institutional Study.
Milonas D, Giesen A, Muilwijk T, Soenens C, Devos G, Venclovas Z
Eur Urol Open Sci. 2024; 66:33-37.
PMID: 39040619
PMC: 11260856.
DOI: 10.1016/j.euros.2024.06.001.
Enhancing prostate cancer diagnosis and reducing unnecessary biopsies with [F]DCFPyL PET/CT imaging in PI-RADS 3/4 patients.
Fu Y, Zhao M, Chen J, Wen Q, Chen B
Sci Rep. 2024; 14(1):15525.
PMID: 38969741
PMC: 11226634.
DOI: 10.1038/s41598-024-65452-z.
The influence of Gleason score ≤ 6 histology on the outcome of high-risk localized prostate cancer after modern radiotherapy.
Yamazaki H, Suzuki G, Masui K, Aibe N, Kimoto T, Yamada K
Sci Rep. 2024; 14(1):8011.
PMID: 38580670
PMC: 10997615.
DOI: 10.1038/s41598-024-55457-z.
Visium spatial transcriptomics reveals intratumor heterogeneity and profiles of Gleason score progression in prostate cancer.
Quan Y, Zhang H, Wang M, Ping H
iScience. 2023; 26(12):108429.
PMID: 38077153
PMC: 10698261.
DOI: 10.1016/j.isci.2023.108429.
MRI-Guided Targeted and Systematic Prostate Biopsies as Prognostic Indicators for Prostate Cancer Treatment Decisions.
Ali F, Sievert K, Eisenblaetter M, Titze B, Hansen T, Barth P
Cancers (Basel). 2023; 15(15).
PMID: 37568731
PMC: 10416861.
DOI: 10.3390/cancers15153915.
Putting patients first to redefine prostate cancer classifications.
Nyame Y, Gore J, Lin D
J Natl Cancer Inst. 2023; 115(11):1249-1251.
PMID: 37463855
PMC: 10637029.
DOI: 10.1093/jnci/djad124.
The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer.
Berlin A, Ramotar M, Santiago A, Liu Z, Li J, Wolinsky H
J Natl Cancer Inst. 2023; 115(11):1364-1373.
PMID: 37285311
PMC: 10637044.
DOI: 10.1093/jnci/djad108.
A Global Perspective on the Controversy of Gleason Score 6 Prostate Cancer Reporting: The Potential Role of Population-Based Cancer Registries.
Farre X, Mousavi S, Marcos-Gragera R, Malaker K
JCO Glob Oncol. 2023; 9:e2200427.
PMID: 37099738
PMC: 10281400.
DOI: 10.1200/GO.22.00427.
Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
Cooperberg M, Meeks W, Fang R, Gaylis F, Catalona W, Makarov D
JAMA Netw Open. 2023; 6(3):e231439.
PMID: 36862409
PMC: 9982696.
DOI: 10.1001/jamanetworkopen.2023.1439.
Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillance-A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting.
Ebner B, Apfelbeck M, Pyrgidis N, Nellessen T, Ledderose S, Pfitzinger P
Bioengineering (Basel). 2023; 10(2).
PMID: 36829741
PMC: 9952076.
DOI: 10.3390/bioengineering10020247.
Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label.
Semsarian C, Ma T, Nickel B, Barratt A, Varma M, Delahunt B
Prostate. 2023; 83(6):498-515.
PMID: 36811453
PMC: 10952636.
DOI: 10.1002/pros.24493.
Gleason 6 prostate cancer: That which cannot be named.
Burke H
Front Oncol. 2022; 12:1073580.
PMID: 36544706
PMC: 9760953.
DOI: 10.3389/fonc.2022.1073580.
Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions.
Phelps T, Yilmaz E, Harmon S, Belue M, Shih J, Garcia C
Abdom Radiol (NY). 2022; 48(3):1079-1089.
PMID: 36526922
PMC: 10765956.
DOI: 10.1007/s00261-022-03775-z.
Reducing Prostate Cancer Overdiagnosis.
Gulati R
N Engl J Med. 2022; 387(23):2187-2188.
PMID: 36477037
PMC: 11392600.
DOI: 10.1056/NEJMe2214658.
